These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 22577108)

  • 1. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
    Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
    Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
    Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
    Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).
    Giusti F; Cianferotti L; Gronchi G; Cioppi F; Masi L; Faggiano A; Colao A; Ferolla P; Brandi ML
    Endocrine; 2016 Jun; 52(3):495-506. PubMed ID: 26224587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet.
    Reh CM; Hendy GN; Cole DE; Jeandron DD
    J Clin Endocrinol Metab; 2011 Apr; 96(4):E707-12. PubMed ID: 21289269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl.
    Rothe HM; Shapiro WB; Sun WY; Chou SY
    Pharmacogenet Genomics; 2005 Jan; 15(1):29-34. PubMed ID: 15864123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet.
    Falchetti A; Cilotti A; Vaggelli L; Masi L; Amedei A; Cioppi F; Tonelli F; Brandi ML
    Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):351-7. PubMed ID: 18414463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.
    Cetani F; Saponaro F; Banti C; Cianferotti L; Vignali E; Chiavistelli S; Viccica G; Pinchera A; Marcocci C
    J Endocrinol Invest; 2012 Jul; 35(7):655-60. PubMed ID: 21971564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors.
    Mingione A; Verdelli C; Terranegra A; Soldati L; Corbetta S
    Curr Cancer Drug Targets; 2015; 15(7):563-74. PubMed ID: 26033088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
    Vestergaard P; Nielsen LR; Mosekilde L
    Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group.
    Saponaro F; Faggiano A; Grimaldi F; Borretta G; Brandi ML; Minisola S; Frasoldati A; Papini E; Scillitani A; Banti C; Del Prete M; Vescini F; Gianotti L; Cavalli L; Romagnoli E; Colao A; Cetani F; Marcocci C
    Clin Endocrinol (Oxf); 2013 Jul; 79(1):20-6. PubMed ID: 23228121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medical treatment of primary hyperparathyroidism: role of calcimimetics].
    Muñoz Torres M; García Martín A
    Endocrinol Nutr; 2009 Apr; 56 Suppl 1():29-34. PubMed ID: 19627758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition.
    Vierimaa O; Villablanca A; Alimov A; Georgitsi M; Raitila A; Vahteristo P; Larsson C; Ruokonen A; Eloranta E; Ebeling TM; Ignatius J; Aaltonen LA; Leisti J; Salmela PI
    J Endocrinol Invest; 2009 Jun; 32(6):512-8. PubMed ID: 19474519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utilization of cinacalcet in hypercalcemic conditions.
    Messa P; Alfieri C; Brezzi B
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):517-28. PubMed ID: 21361849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, before and after Parathyroidectomy.
    Marini F; Giusti F; Cioppi F; Maraghelli D; Cavalli T; Tonelli F; Brandi ML
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neonatal hypercalcemia due to a homozygous mutation in the calcium-sensing receptor: failure of cinacalcet.
    García Soblechero E; Ferrer Castillo MT; Jiménez Crespo B; Domínguez Quintero ML; González Fuentes C
    Neonatology; 2013; 104(2):104-8. PubMed ID: 23817301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
    Khan A; Bilezikian J; Bone H; Gurevich A; Lakatos P; Misiorowski W; Rozhinskaya L; Trotman ML; Tóth M
    Eur J Endocrinol; 2015 May; 172(5):527-35. PubMed ID: 25637076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathogenesis of primary hyperparathyroidism.
    Cetani F; Pardi E; Borsari S; Marcocci C
    J Endocrinol Invest; 2011 Jul; 34(7 Suppl):35-9. PubMed ID: 21985978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis.
    Akinci B; Comlekci A; Tankurt E
    Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):142-5. PubMed ID: 18561096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.
    Duntas LH; Stathatos N
    Endocrine; 2011 Jun; 39(3):199-204. PubMed ID: 21442382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.